Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects

NCT ID: NCT01598649

Last Updated: 2013-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to elucidate the effects of lupin protein (Lupinus angustifolius Boregine) as part of a mixed diet on cardiovascular risk factors and to clarify the role of arginine, one of the most abundant amino acids in lupin protein.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is based on a previous finding that a daily dosage of 25 g lupin protein isolate, administered as protein drinks, is capable to influence the plasma lipids positively.

Consequently, the physiological effects of a mixed diet containing 25 g lupin protein isolate per day will be investigated compared to 1) a diet containing 25 g of milk protein as well as to 2) a diet with 25 g milk protein and additionally the amino acid arginine supplemented daily.

A double-blinded, controlled, randomized cross-over trial will be performed. Altogether 75 volunteers with hypercholesterolemia will be divided into three groups of 25 subjects each. After a run-in period (baseline), the first group will consume foods with lupin protein isolate (group A), the second group will receive the same foods with milk protein isolate (group B) and the third group will consume the foods with milk protein and 1,6 g arginine per day over a period of four weeks. After a wash-out period of six weeks, the diet will be crossed within the three groups for a second intervention period of four weeks. After another wash-out period, diet will be crossed within the three groups once again.

Arginine will be provided as capsule (1,6 g per day = four capsules per day) in one of the two groups receiving foods with milk protein. In the other groups (receiving foods with lupin protein or milk protein only) four placebo capsules will be served, containing mannitol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dietary protein Lupin protein Cholesterol metabolism Protein metabolism Hypercholesterolemia Protein-enriched foods

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lupin protein

Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol

Group Type EXPERIMENTAL

Fabricated foods with lupin protein

Intervention Type DIETARY_SUPPLEMENT

\- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)

Mannitol

Intervention Type DIETARY_SUPPLEMENT

\- Placebo capsules containing mannitol (four capsules per day)

Milk protein

Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules

Group Type ACTIVE_COMPARATOR

Mannitol

Intervention Type DIETARY_SUPPLEMENT

\- Placebo capsules containing mannitol (four capsules per day)

Fabricated foods with milk protein

Intervention Type DIETARY_SUPPLEMENT

Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)

Milk protein and arginine

Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day

Group Type ACTIVE_COMPARATOR

Arginine

Intervention Type DIETARY_SUPPLEMENT

\- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)

Fabricated foods with milk protein

Intervention Type DIETARY_SUPPLEMENT

Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fabricated foods with lupin protein

\- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)

Intervention Type DIETARY_SUPPLEMENT

Mannitol

\- Placebo capsules containing mannitol (four capsules per day)

Intervention Type DIETARY_SUPPLEMENT

Arginine

\- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)

Intervention Type DIETARY_SUPPLEMENT

Fabricated foods with milk protein

Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate Hypercholesterolemia (total cholesterol \>= 5.2 mmol/L)
* Age: 20-80 years

Exclusion Criteria

* Intake of lipid-lowering pharmaceuticals
* Allergy against legumes
* Intolerance or allergy against milk
* Pregnancy, lactation
* Chronic bowel diseases
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

German Federal Ministry of Education and Research

OTHER_GOV

Sponsor Role collaborator

University of Jena

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerhard Jahreis

Prof. Dr. habil.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerhard Jahreis, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutritional Physiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Friedrich Schiller University Jena, Department of Nutritional Physiology

Jena, Thuringia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Bahr M, Fechner A, Kiehntopf M, Jahreis G. Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: a randomized controlled trial. Clin Nutr. 2015 Feb;34(1):7-14. doi: 10.1016/j.clnu.2014.03.008. Epub 2014 Apr 1.

Reference Type DERIVED
PMID: 24746974 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSEP H52-12

Identifier Type: -

Identifier Source: org_study_id